ASX:CDY - Cellmid Ltd Research
New Lyramid CEO Appointment
On the 28th May 2019, Cellmid announced the appointment of Bart Wuurman as CEO of the company’s Lyramid subsidiary.
The primary purpose of the appointment is to allow Mr. Wuurman to drive a licensing or partnership agreement for Cellmid’s extensive IP over Midkine antibodies.
Notable achievements by Mr. Wuurman include his role as CEO at AM-Pharma where he achieved a €600m option deal with Pfizer.
We believe this news is positive for several reasons.
Firstly, given the track record of Mr. Wuurman, we think this appointment will increase the likelihood of generating a successful partnership or commercial outcome for Cellmid’s Midkine assets.
Secondly, Mr. Wuurman’s remuneration package includes options which are granted upon achieving a successful outcome, which is a vote of confidence by Mr. Wuurman as to the marketability of Cellmid’s Midkine assets.